Fab i inhibitors
Abstract
The open-style of invention (I) compounds or salts of its medicinal, it is FabI inhibitor, used to treat bacterial infections. In by in type in the, (a,) is (a), and (b), and (c), and (d), and (e), and (f), and (g), and (h), and (I), and (j), and (k), and (l), and (m), and (n), and (o) or (p); (I) in the R1 is h or C1-4 alkyl; R2 is h, and C1-4 alkyl or C3-6 ring alkyl; R3 is (q), and (r), and (s), and (t), and (u), and (v) or (w); R4 is h or C1-4 alkyl; (x) Said two a specified of key one of is double bond, another is single; Dang with connection of key is double bond Shi R5 is CH2, or Dang with connection of key is single Shi R5 is h or C1-4 alkyl; R6 is h or C1-4 alkyl; R7 is h or C1-6 alkyl or-C0-6 alkyl-Ar;Y is h, and C1-4 alkyl, and n (R') 2, and NHC (O) R', and NHCH2C (O) R' or NHC (O) CH=CHR'; each x respectively is h, and C1-4 alkyl, and CH2OH, and OR', and SR', and CN, and n (R') 2, and CH2N (R') 2, and NO2, and CF3, and CO2R', and CON (R') 2, and COR', and NR'C (O) R', and f, and Cl, and Br, and I or-s (O) rCF3;W is s or O;Q is h or C1-4 alkyl; m is CH2 or O;L is CH2 or c (O); e is o or NR'; each R' respectively is h, and C1-6 alkyl or-C0-6 alkyl-Ar ; And r is 0, 1, or 2.

Term
No projected expiry on record.
- Priority
- Filed
- Published
- Today
1 claim: 1 independent, 0 dependent
- 1<Our <Our
15 paragraphs in 1 section, as filed
(21) Application no. (22) Introduction Day (24) Running day (41) Aim. avail.
2002.04.05
2000.10.06
2002.06.05 (86) Int. Day and application number (85) Continuation day (30) Priority
2000.10.06, PCT / USOO / 27844 2002.04.05
1999.10.08, US, 158704 (71) Seeking (72) Inventor (74) Proxy
SmithKline Beecham Corp, PO Box 7929, Philadelphia, PA 19103, US
William H Miller, Collegeville, PA 19426, US
Kenneth Allen Newlander, West Chester, PA 19382, US
Mark A Seefeld, Collegeville, PA 19426, US
Irene Nijole Uzinskas, Villanova, PA 19085, US
Walter E DeWolf Jr., Glenmoore, PA 19343, US
Dalia R. Jakas, Norristown, PA 19403, US
Bryns Zacco AS, 0106 Oslo (54) Designation FAB I inhibitors (57) Summary
Compounds of formula (I) are described as Fab I inhibitors and are useful in the treatment of bacterial infections. In said formula, (A) (a), (b), (c), (d), (e), (f), (g), (h), (i), 0), (k), 0), (m), (n), (o) or (p); (I) wherein R<sup>1</sup> or H is C1-4 alkyl; R<sup>2</sup> is H, Cj. 4alkyl or C<sub>3</sub>.<sub>6</sub>cycloalkyl; R<sup>3</sup> are (q), (r), (s), (t), (u), (v) or (w); R<sup>4</sup> is H or Ci. 4alkyl; (x) indicates that one of the indicated bonds is a double bond and the other is a single bond; R<sup>5</sup> is CH 2 when the bond to which it is bound is a double bond; or R<sup>5</sup> is H or C 1-4 alkyl when the bond to which it is attached is a single bond; R<sup>6</sup> is H or Cualkyl; R<sup>7</sup> is H, Cualkyl or -C 1-4 alkyl-Ar; Y is H, Cualkyl, N (R ')<sub>2</sub>, NHC (O) R ', NHCH<sub>2</sub>C (O) R 'or NHC (O) CH = CHR'; each X is independently H, Cualkyl, CH<sub>2</sub>OH, OR ', SR', CN, N (R ')<sub>2</sub>, CH<sub>2</sub>N (R ')<sub>2</sub>, NO<sub>2</sub>, CF<sub>3</sub>, CO<sub>2</sub>R ', CON (R')<sub>2</sub>, COR ', NR'C (O) R', F, Cl, Br, I or -S (O)<sub>r</sub>CF<sub>3</sub>; W is S or O, Q is H or Cualkyl; M is CH<sub>2</sub> or 0; L is CH<sub>2</sub> or C (O); E is O or NR '; each R 1 is independently H, C 1-6 alkyl or -C 1-6 alkyl-Ar; and r is 0.1 or 2; or a pharmaceutically acceptable salt thereof.
<img file="NO20021638A_D0001.tif" />
1 sheet
Sheet 1
52 members in 25 offices
Priority claims8
| Document | Office | Kind | Date |
|---|---|---|---|
| 15870499 | United States of America | P | |
| 15870499 | United States of America | P | |
| 0027844 | United States of America | W | |
| 0027844 | United States of America | W | |
| 0027844 | – | – | – |
| 158704 | – | – | – |
| US19990158704P | – | – | – |
| WO2000US27844 | – | – | – |
Members52
| Document | Office | Kind | |
|---|---|---|---|
| CA2387016A1 | Canada | A1 | |
| WO0127103A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU7874700A | Australia | A | |
| UY26380A1 | Uruguay | A1 | |
| PE20010635A1 | Peru | A1 | |
| NO20021638D0 | Norway | D0 | |
| ECSP003699A | Ecuador | A | |
| KR20020037770A | Republic of Korea | A | |
| NO20021638LThis record | Norway | L | |
| CZ20021167A3 | Czechia | A3 | |
| EP1226138A1 | European Patent Office (EPO) | A1 | |
| IL148820D0 | Israel | D0 | |
| BR0014470A | Brazil | A | |
| CN1378542A | China | A | |
| AR025976A1 | Argentina | A1 | |
| HU0203122A2 | Hungary | A2 | |
| HUP0203122A2 | Hungary | A2 | |
| EP1226138A4 | European Patent Office (EPO) | A4 | |
| JP2003511448A | Japan | A | |
| HK1049656A1 | Hong Kong, China | A1 | |
| ZA200202631B | South Africa | B | |
| TW534909B | Taiwan Province of China | B | |
| HU0203122A3 | Hungary | A3 | |
| HUP0203122A3 | Hungary | A3 | |
| NZ517706A | New Zealand | A | |
| PL354892A1 | Poland | A1 | |
| AU773218B2 | Australia | B2 | |
| EP1226138B1 | European Patent Office (EPO) | B1 | |
| AT285821T | Austria | T | |
| ATE285821T1 | Austria | T1 | |
| US6846819B1 | United States of America | B1 | |
| DE60017180D1 | Germany | D1 | |
| CN1197860C | China | C | |
| ES2231275T3 | Spain | T3 | |
| US2005250810A1 | United States of America | A1 | |
| DE60017180T2 | Germany | T2 | |
| NO322708B1 | Norway | B1 | |
| IL148820A | Israel | A | |
| KR100823382B1 | Republic of Korea | B1 | |
| US2008125423A1 | United States of America | A1 | |
| US7524843B2 | United States of America | B2 | |
| PL201627B1 | Poland | B1 | |
| US7557125B2 | United States of America | B2 | |
| US2009275572A1 | United States of America | A1 | |
| US7790716B2 | United States of America | B2 | |
| CZ302015B6 | Czechia | B6 | |
| CA2387016C | Canada | C | |
| US2011190283A1 | United States of America | A1 | |
| JP4803935B2 | Japan | B2 | |
| US8173646B2 | United States of America | B2 | |
| HU230030B1 | Hungary | B1 | |
| BRPI0014470B1 | Brazil | B1 |
2 legal events, as the office reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | |
|---|---|---|
| Lapsed by not paying the annual feesLapsedMM1K | MM1K | |
| Change of the owner's name or address (par. 44 patent law, par. patentforskriften)CHAD | CHAD |
Numbers
- Publication, DOCDB
- 20021638
- Publication, EPODOC
- NO20021638L
- Application
- 1638
- Application, DOCDB
- 20021638
- Application, EPODOC
- NO20020001638
Titles2
- Norwegian
- FAB I-inhibitorer
- English
- FAB I inhibitors
Classification
- CPC, 23
- C07D209/14
- C07D213/75
- A61K31/381
- A61K31/4436
- A61K31/4439
- A61K31/47
- A61K31/495
- A61K31/506
- A61K31/5365
- C07D209/52
- C07D239/42
- C07D401/12
- C07D405/12
- C07D471/04
- C07D487/04
- C07D495/04
- A61P31/00
- A61P31/04
- A61P43/00
- Y02A50/30
- C07D209/24
- C07D333/52
- C07D498/04
- IPC, 33
- A61K31 381
- A61K31 4045
- A61K31 407
- A61K31 44
- A61K31 443
- A61K31 4436
- G01N33 50
- A61K31 4439
- A61K31 444
- A61K31 47
- A61K31 4709
- A61K31 495
- A61K31 506
- A61K31 519
- A61K31 5365
- A61K31 5383
- A61P31 04
- A61P43 00
- C07D209 14
- C07D209 52
- C07D213 73
- C07D213 75
- C07D239 42
- C07D401 12
- C07D401 14
- C07D403 12
- C07D405 12
- C07D409 12
- C07D471 04
- C07D487 04
- C07D495 04
- C07D498 04
- G01N33 15